PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial.

Abstract  To examine the effect on BRCA testing and mastectomy rates of a widely viewed 2013 New York Times editorial by public figure Angelina Jolie that endorsed BRCA testing and announced Jolie's decision to undergo preventive mastectomy.
PMID
Related Publications

Celebrity Influence and Identification: A Test of the Angelina Effect.

The Angelina effect: immediate reach, grasp, and impact of going public.

Celebrity Health Announcements and Online Health Information Seeking: An Analysis of Angelina Jolie's Preventative Health Decision.

Angelina Jolie's faulty gene: newspaper coverage of a celebrity's preventive bilateral mastectomy in Canada, the United States, and the United Kingdom.

The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use.

Authors

Mayor MeshTerms

Famous Persons

Periodicals as Topic

Keywords
Journal Title bmj (clinical research ed.)
Publication Year Start




PMID- 27974323
OWN - NLM
STAT- MEDLINE
DA  - 20161215
DCOM- 20170327
LR  - 20170817
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 355
DP  - 2016 Dec 14
TI  - Do celebrity endorsements matter? Observational study of BRCA gene testing and
      mastectomy rates after Angelina Jolie's New York Times editorial.
PG  - i6357
LID - 10.1136/bmj.i6357 [doi]
AB  - OBJECTIVE: To examine the effect on BRCA testing and mastectomy rates of a widely
      viewed 2013 New York Times editorial by public figure Angelina Jolie that
      endorsed BRCA testing and announced Jolie's decision to undergo preventive
      mastectomy. DESIGN: Observational study with difference-in-difference analysis.
      SETTING: Commercially insured US population. PARTICIPANTS: Women aged 18-64 years
      with claims in the Truven MarketScan commercial claims database (n=9 532 836).
      MAIN OUTCOME MEASURES: Changes in BRCA testing rates in the 15 business days
      before versus after 14 May 2013 (editorial date) compared with the change in the 
      same period in 2012; mastectomy rates in the months before and after publication,
      both overall and within 60 days of BRCA testing among women who were tested;
      national estimates of incremental tests and expenditures associated with Jolie's 
      article in the 15 days after publication. RESULTS: Daily BRCA test rates
      increased immediately after the 2013 editorial, from 0.71 tests/100 000 women in 
      the 15 business days before to 1.13 tests/100 000 women in the 15 business days
      after publication. In comparison, daily test rates were similar in the same
      period in 2012 (0.58/100 000 women in the 15 business days before 14 May versus
      0.55/100 000 women in the 15 business days after), implying a
      difference-in-difference absolute daily increase of 0.45 tests/100 000 women or a
      64% relative increase (P<0.001). The editorial was associated with an estimated
      increase of 4500 BRCA tests and $13.5m ( pound10.8m; euro12.8) expenditure
      nationally among commercially insured adult women in those 15 days. Increased
      BRCA testing rates were sustained throughout 2013. Overall mastectomy rates
      remained unchanged in the months after publication, but 60 day mastectomy rates
      among women who had a BRCA test fell from 10% in the months before publication to
      7% in the months after publication, suggesting that women who underwent tests as 
      a result of to the editorial had a lower pre-test probability of having the BRCA 
      mutation than women tested before the editorial. CONCLUSIONS: Celebrity
      endorsements can have a large and immediate effect on use of health services.
      Such announcements can be a low cost means of reaching a broad audience quickly, 
      but they may not effectively target the subpopulations that are most at risk for 
      the relevant underlying condition.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not
      already granted under a licence) please go to
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Desai, Sunita
AU  - Desai S
AD  - Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave,
      Boston, MA 02115, USA.
FAU - Jena, Anupam B
AU  - Jena AB
AD  - Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave,
      Boston, MA 02115, USA [email protected]
AD  - Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
AD  - National Bureau of Economic Research, Cambridge, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161214
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Breast Neoplasms/economics/*epidemiology/genetics/surgery
MH  - *Famous Persons
MH  - Genes, BRCA1
MH  - Genes, BRCA2
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing/economics/*statistics & numerical data
MH  - Humans
MH  - Insurance, Health
MH  - Mastectomy/economics/*statistics & numerical data
MH  - Middle Aged
MH  - *Periodicals as Topic
MH  - Time Factors
MH  - United States/epidemiology
MH  - Young Adult
PS  - Jolie A
FPS - Jolie, Angelina
PMC - PMC5156611
COI - All authors have completed the ICMJE uniform disclosure form at
      www.icmje.org/coi_disclosure.pdf (available on request from the corresponding
      author) and declare: support provided by grants from the Office of the Director, 
      National Institutes of Health, and the Marshall J Seidman fellowship at Harvard
      Medical School; ABJ has received consulting fees unrelated to this work from
      Pfizer, Hill Rom Services, Bristol Myers Squibb, Novartis Pharmaceuticals, Vertex
      Pharmaceuticals, and Precision Health Economics, a company providing consulting
      services to the life sciences industry; no other relationships or activities that
      could appear to have influenced the submitted work.
EDAT- 2016/12/16 06:00
MHDA- 2017/03/28 06:00
CRDT- 2016/12/16 06:00
PST - epublish
SO  - BMJ. 2016 Dec 14;355:i6357. doi: 10.1136/bmj.i6357.